Category - Developments

Developments

REGENXBIO completes dosing for Phase 1/2a wet AMD trial

REGENXBIO (NASDAQ:RGNX) has completed dosing in its Phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). RGX-314 uses REGENXBIO’s proprietary NAV gene delivery platform to...

May 31, 2019

Developments

Zenabis posts Q1 net revenue of $11.6-million; anticipates range of $26-millon to $30-million for Q2

Zenabis Global (TSX:ZENA) posted net revenue of $11.6-million from its cannabis and propogation segment for the first quarter of 2019, up from $3.4-million in the fourth quarter of 2018, which included only its cannabis...

May 31, 2019

Developments

BriaCell technology and clinical data published at the 2019 ASCO

BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...

May 31, 2019

Developments

Scientus Pharma receives Health Canada approval to sell cannabis oils and capsules

Closely-held Scientus Pharma received authorization under Health Canada’s cannabis regulations for the sale of cannabis oils and capsules for medical purposes. The company previously obtained its Health Canada license...

May 28, 2019

Developments

IntelGenx receives first shipment of cannabis extract from Tilray for cannabis-infused oral film

IntelGenx (TSXV:IGX; OTCQX:IGXT) recently received the first shipment of cannabis extract from Tilray (NASDAQ:TLRY), providing it with sufficient quantities to commence batch production of cannabis-infused VersaFilm...

May 28, 2019

Developments

OncoSec Medical doses first patient in head and neck cancer trial

OncoSec Medical (NASDAQ:ONCS) dosed the first patient in a trial assessing a triple drug combination, which includes OncoSec’s TAVO, in patients with unresectable squamous cell carcinoma head and neck (SCCHN) cancer...

May 24, 2019

Developments

FDA approves REGENXBIO gene therapy for pediatric spinal muscular atrophy

The FDA approved REGENXBIO’s (NASDAQ:RGNX) ZOLGENSMA for the treatment of spinal muscular atrophy (SMA) in pediatric patients who are less than two years of age. Caused by a genetic defect in the SMN1 gene, SMA is...

May 24, 2019

Developments

Neovasc reports positive two-year data for Reducer device

Neovasc (NASDAQ:NVNC) reported positive long term safety and efficacy data for its Reducer device in 50 patients suffering from refractory disabling angina. Neovasc’s Reducer relives angina symptoms by altering blood...

May 24, 2019

Developments

Iovance cervical cancer therapy gets FDA breakthrough designation

Iovance Biotherapeutics (NASDAQ:IOVA) LN-145 received FDA breakthrough therapy designation in recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy. Designed to...

May 24, 2019

Developments

Zenabis graduates to the TSX

Zenabis Global Inc. (TSXV:ZENA) received approval to list its common shares and outstanding listed common share purchase warrants on the TSX.

May 24, 2019

Category - Developments

Subscribe